Magnifying LeNS Archives - Page 3 of 7

ASCO 2023: Progress for Metastatic (Stage 4) Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-07-25T15:04:43-05:00July 25th, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]

2

ASCO 2023: Advances in Early-Stage Lung Cancer Research

Bethany Johnson (GO2 for Lung Cancer)2023-07-25T15:03:51-05:00July 25th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]

0

ASCO 2023: New Advances in Lung Cancer Screening

Bethany Johnson (GO2 for Lung Cancer)2023-07-25T14:10:22-05:00July 25th, 2023|Hot Topics, Magnifying LeNS, Newsletter Articles|

By Heather Law, MA, Associate Director, GO2’s Lung Cancer Registry Lung cancer screening is unavailable for many people at risk for lung cancer. At the 2023 American Society of Clinical Oncology (ASCO) meeting, early results from groundbreaking studies offered [...]

1

New Study to Understand Why Cancers Progress After Using KRAS Inhibitors

Bethany Johnson (GO2 for Lung Cancer)2023-02-09T09:37:51-06:00February 9th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Jennifer C. King, PhD, Chief Scientific Officer GO2 for Lung Cancer has launched the SPARK Study to help understand cancer driven by changes in the KRAS gene. This study is through our medical research consortium, ALCMI (Addario Lung [...]

1

A Year of Growth for GO2 Research

Bethany Johnson (GO2 for Lung Cancer)2023-02-09T09:35:15-06:00February 9th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Andrew Ciupek, PhD, Associate Director of Clinical Research; Heather Law, MA, Associate Director of Lung Cancer Registry; Shanada Monestime, PharmD, BCOP, Director of Community Engaged Research; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program 2022 was an exciting [...]

0

FDA Approvals: New Treatment Landscape in 2023

Bethany Johnson (GO2 for Lung Cancer)2023-02-09T09:30:27-06:00February 9th, 2023|Magnifying LeNS, Newsletter Articles, Science and Research|

Authors: Renee Botello, MSc, Treatment and Trial Navigator; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program In 2022, the treatment landscape for lung cancer continued to evolve to provide breakthrough treatment options for people living with lung cancer. This [...]

1

Advances in Precision Medicine for Late Stage Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-09-20T12:44:58-05:00October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research, Small Cell Lung Cancer|

Authors: Renee Botello, MSc., Treatment and Trials Navigator; Andrew Ciupek, PhD, Associate Director, Clinical Research; Chief Scientific Officer Jennifer C. King, PhD; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research Every person’s cancer is different, which is why we [...]

1

GO2 for Lung Cancer’s Presence at The World Conference on Lung Cancer 2022

Bethany Johnson (GO2 for Lung Cancer)2022-10-27T10:02:18-05:00October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Brittney Nichols, MPH, BSN-RN, Specialist, Science and Research This summer, the World Conference on Lung Cancer convened in Vienna, Austria. GO2 shared our research with this community as both lead authors and collaborators on several projects to help [...]

1

Advances in Treatment for Early Stage Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2022-10-27T09:52:39-05:00October 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, [...]

0

Targeted Therapy Treatment Updates from ASCO 2022

Bethany Johnson (GO2 for Lung Cancer)2022-06-27T06:58:14-05:00June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]

1